Tagged with Bayer

China The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, and Sanofi have achieved China growth in the first half of the year despite pricing squeezes on their mature brands; and why Bayer sees huge growth potential…

Turkey Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer to global organisations, why the well-educated and cost-efficient domestic labour force is so important to the Turkish pharma market’s future,…

Saudi Arabia Clinical trials provide a pathway to innovation for clinicians and patients in countries like Saudi Arabia and form a key element of the country’s Vision 2030 national plan. As Saudi transitions away from oil towards becoming a knowledge-based economy, it is hoping to attract ever more international pharma companies to…

Turkey Almost two decades after initiating large-scale health system reforms, Turkey has consolidated the provision of universal healthcare coverage to over 95 percent of the population. The effort, part of the country’s Health Transformation Program introduced in 2003, has been commended by international organizations across the world. But today, as citizens…

Colombia The latest news from the Colombian pharma market, including a new (legal) US cannabis deal; Bayer’s updated regional strategy; a pandemic-induced OTC product boom; Faes Farma’s growth; and why prostate cancer remains a significant concern in the country.   Colombia-Based Clever Leaves To Donate $25 Million Worth Of Cannabis To…

Saudi Arabia Hussein El Hakim, managing director for Bayer Saudi Arabia and general manager for its pharmaceuticals division in the country, discusses the affiliate’s rapid expansion after years of double-digit growth. El Hakim explains how the German Life Science company is approaching the transformation of the Saudi healthcare market, with changes in…

China The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta; the Big Pharma losers from the latest round of price cuts for off-patent drugs; Lonza’s new investment in Chinese API manufacturing expansion; and Dingdang Health’s recent USD 220 million financing round.   Yescarta…

Turkey Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure and the advantages of Bayer’s longstanding relationship in both markets with a track record of six decades. In addition, Drechsel explains how the German company has moved from fifth…

Mexico The latest news from Mexican pharma, including Bayer’s big bet on oncology and Novartis’ aggressive expansion strategy as well as updates on the country’s vaccination drive, including the upcoming rollout of the J&J jab, why the country’s doctors are being denied vaccines, and the progression of trials for the Sanofi…

Saudi Arabia Historically dependent on oil, Saudi Arabia, like most countries in the Arabian Peninsula, is now investing a large chunk of the sizeable resources obtained from fossil fuels in diversifying its economy. Pharmaceuticals, as one of the strategic sectors in the country’s diversification strategy, has reaped the benefits and the Saudi…

France The Top 10 pharma companies in the EUR 28.9 million French pharma market in 2019. Homegrown players Sanofi and Servier lead the way, followed by Bayer, Janssen and Mylan. French firms Pierre Fabre, Merial and Ceva Sante also make the list, while AstraZeneca and Teva round out the Top 10.…

Germany A roundup of some of the most important recent news from German pharma, including state honours for the founders of BioNTech, the latest on vaccines and lockdowns in the country, as well as the German pharma firms making international investments and predicting mid-term growth.   Pharma companies must deliver promised…